Physician profile
Ellis B Charles
NPI 1013046341
$2,679.25
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $389 · 2020: $418 · 2021: $436 · 2022: $282 · 2023: $872 · 2024: $281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,153.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,444.09 | 2021-2024 | Vraylar |
| Allergan, INC. | $470.94 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $201.88 | 2019-2024 | Rexulti |
| Sunovion Pharmaceuticals INC. | $175.42 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $141.71 | 2019-2023 | Spravato |
| Alkermes, INC. | $91.21 | 2021-2024 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $71.52 | 2022-2023 | |
| Noven Therapeutics, LLC | $28.83 | 2020 | |
| Vanda Pharmaceuticals INC. | $24.79 | 2021-2024 | Fanapt |
| Neurocrine Biosciences, INC. | $14.94 | 2024 | Ingrezza |
| Indivior INC. | $13.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellis Charles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.